Failure to recognize and respond to how rapidly illegal drug markets have changed with the arrival of illegally manufactured synthetic opioids will continue to put many Americans at risk of exposure to fentanyl, endangering the lives of hundreds of thousands more for years to come.
For decades, elected officials brushed off harm reduction as a viable option for reducing the harms of drug use over concerns of enabling drug consumption. But now, these strategies are front and center, spoken aloud, from the largest podium in the land, and during prime time. What caused this historic about-face?
This study examined the rates of subsequent buprenorphine treatment for buprenorphine-naïve individuals filling buprenorphine prescriptions from emergency physicians and initiated buprenorphine treatment and how such rates varied before and during the COVID-19 pandemic.
Most people who fill prescriptions from emergency physicians to treat their opioid use disorder do not continue to receive the medication, suggesting new approaches are needed to help people continue drug treatment begun on an emergency basis.
Synthetic opioids are likely to increasingly reach illegal drug markets. Failure to recognize and respond to how rapidly drug markets have changed with the arrival of illegally manufactured synthetic opioids will continue to put many at risk of exposure to fentanyl, endangering the lives of hundreds of thousands more Americans for years to come.
Substance use disorders are common among sex trafficking victims. Drugs or alcohol may be used to lure, coerce, or control them, and they may use substances to cope with trauma. This creates barriers to accessing treatment, support services, and assistance from criminal justice agencies.
Some communities hard hit by the opioid crisis are interested in opening supervised consumption sites—places where people who use drugs can do so under supervision of trained staff. What could be done to make it easier to pilot and evaluate these sites in the United States?
RAND researchers provide a toolkit to support the delivery of effective, evidence-based pharmacotherapy for clients with co-occurring substance use and mental health disorders and simplify care implementation in mental health clinics.
Researchers and clinicians provide a guide for identifying clients with co-occurring opioid use and mental health disorders in mental health settings and treating these clients with an appropriate opioid use disorder medication.
To understand patterns of use and interest in quitting different types of tobacco products among youth experiencing homelessness, a RAND team surveyed these youth in Los Angeles County to inform efforts to reduce their use of tobacco products.
Australia is at risk of a fentanyl problem, but it is better prepared than North America. If the country can make the same kind of concerted effort it did to keep COVID-19 at bay, that could save thousands of lives.
This is the first study to evaluate the feasibility of using a text messaging-based intervention (TMI) for behavior change with 18–25 year olds experiencing homelessness, and the first to test a TMI to provide ongoing support for smoking cessation.
In this RAND Remote presentation, Beau Kilmer discusses how RAND is identifying and evaluating innovative approaches to tackle some of America's most pressing drug problems and help strengthen and safeguard communities.
While many illegally manufactured potent synthetic opioids (IMPSO) are produced in Asia, there is little evidence they have entered markets there. We consider the susceptibility to IMPSO's encroachment in markets in the Asia-Pacific region.